Evidence map›Paper›PMID 34841435›Full record

ArticleMolecular medicine reports2022

MicroRNA‑671‑5p inhibits cell proliferation, migration and invasion in non‑small cell lung cancer by targeting MFAP3L.

Junhui Ye, Wujun Luo, Lingling Luo, Limin Zhai, Pingping Huang

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Molecular medicine reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. A review on the role of miR-671 in human disorders.Frontiers in molecular biosciences · 2022
    Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Junhui Ye *Department of Respiratory Medicine, The People's Hospital of Sanmen, Taizhou, Zhejiang 317100, P.R. China.
Wujun Luo *Department of Respiratory Medicine, The People's Hospital of Sanmen, Taizhou, Zhejiang 317100, P.R. China.
Lingling LuoDepartment of Respiratory Medicine, The People's Hospital of Sanmen, Taizhou, Zhejiang 317100, P.R. China.
Limin ZhaiDepartment of Respiratory Medicine, The People's Hospital of Sanmen, Taizhou, Zhejiang 317100, P.R. China.
Pingping HuangDepartment of Respiratory Medicine, The People's Hospital of Sanmen, Taizhou, Zhejiang 317100, P.R. China.
Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA (miR)‑671‑5p serves as a tumor suppressor in several types of cancer, including gastric and breast cancer. However, the function of miR‑671‑5p in non‑small cell lung cancer (NSCLC) has not been described in detail. The present study aimed to investigate the role of miR‑671‑5p in NSCLC. The expression levels of miR‑671‑5p were determined in NSCLC tissue samples and cell lines using reverse transcription‑quantitative PCR. Prediction of miR‑671‑5p targets was performed using the TargetScan database and verified by luciferase reporter assay and western blot analysis. Functional experiments, including Cell Counting Kit‑8, wound healing and Transwell assays, were performed in NSCLC cells. The results of the present study demonstrated that lower expression levels of miR‑671‑5p were observed in NSCLC tissues and cell lines compared with those in the corresponding controls. Low miR‑671‑5p levels were significantly associated with an advanced Tumor‑Node‑Metastasis stage and lymph node metastasis in patients with NSCLC. Microfibril‑associated protein 3‑like (MFAP3L) was confirmed to be a direct target of miR‑671‑5p. The proliferative, migratory and invasive abilities of NSCLC cells were suppressed following transfection with miR‑671‑5p mimics and promoted by the miR‑671‑5p inhibitor compared with those in the respective control groups. In addition, the effects of miR‑671‑5p on cell proliferation, migration and invasion, as well as the expression levels of proliferating cell nuclear antigen, E‑cadherin, N‑cadherin and vimentin were reversed by MFAP3L overexpression. In conclusion, targeting the miR‑671‑5p/MFAP3L signaling pathway may be a promising therapeutic strategy for NSCLC treatment.

Indexed as

A549 CellsCarcinoma, Non-Small-Cell LungCell Line, TumorCell MovementCell ProliferationContractile ProteinsFemaleGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansLung NeoplasmsLymphatic MetastasisMaleMicroRNAsMiddle AgedWound HealingContractile ProteinsMFAP3 protein, humanMicroRNAsMIRN671 microRNA, humanmetastasismicrofibril‑associated protein 3‑likemicroRNA‑671‑5pnon‑small cell lung cancerproliferation

Identifiers

PMID34841435
PMCPMC8669681
OpenAlexW3214895308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.